In fact, progesterone receptors are one of the most common therapeutic targets in uLM management due to the use of selective progesterone receptor modulators, including ulipristal acetate (UPA) or mifepristone, that can inhibit proliferation, increase apoptosis, and reduce tumor growth and symptoms [30,31]. This evidence concerns the gene PGR and neoplasm.